Clinical trial
ABE-DESCART Study: Characterization and Outcomes of Patients With Relapsed and Refractory Multiple Myeloma Eligible for Treatment or Treated With Abecma© (Idecabtagene Vicleucel) in Real World Setting in France. A Database Analysis Based on the DESCAR-T Registry
NCT06154902 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- ABE-DESCART Study: Characterization and Outcomes of Patients With Relapsed and Refractory Multiple Myeloma Eligible for Treatment or Treated With Abecma© (Idecabtagene Vicleucel) in Real World Setting in France. A Database Analysis Based on the DESCAR-T Registry
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Observational
- Overall status
- Active, not recruiting
- Start date
- July 29, 2022
- Completion date
- December 31, 2027
- Enrollment
- 350 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.